[Asia Economy Reporter Hyun-ui Cho] TK M, a biopharmaceutical subsidiary of Kolmar Holdings, will change its name to HK Bio Innovation.
On the 9th, HK Bio Innovation announced this and stated, "The new name embodies our determination to leap forward as a global biopharmaceutical company through innovative product development."
Based on over 20 years of accumulated expertise in biopharmaceutical research, development, and production, HK Bio Innovation plans to expand its scope beyond contract development and manufacturing organization (CDMO) services to include advanced biopharmaceutical development through active open innovation.
Lee Dong-eok, CEO of HK Bio Innovation, said, "We will take on new challenges to become a century-old company leading the global bio industry."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
